Evidence map›Paper›PMID 41345264›Full record

Trial reportBritish journal of cancer2026

Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer.

Noboru Yamamoto, Dong Yan, Vinod Ganju, Xinfang Hou, Hongming Pan, Jianzhen Shan, Liwei Wang, Sang-We Kim, Gary Richardson, Rachel E Sanborn and 7 more

2 registry-linked trialsAbstract readClinical Trial, Phase IIMulticenter StudyClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04585035 phase1 / phase2active not recruitingnot on this map

A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation

TypeinterventionalSponsorInventisBio Co., LtdRan2020 to 2025Enrolled180ConditionsSolid Tumor, Adult, NSCLC, CRCArmsD-1553, D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other
NCT05383898 phase1 / phase2completednot on this map

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors

TypeinterventionalSponsorInventisBio Co., LtdRan2021 to 2024Enrolled225ConditionsNSCLCArmsD-1553
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. RAS-targeted therapies for pancreatic cancer.ESMO gastrointestinal oncology · 2026
    Review
  2. Precision Targeting ofInternational journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Noboru YamamotoNational Cancer Center Hospital, Tokyo, Japan.
Dong YanBeijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China.ORCID http://orcid.org/0000-0003-2483-4029
Vinod GanjuPeninsula and Southeast Haematology and Oncology Group, Frankston, Australia.
Xinfang HouHenan Cancer Hospital, Zhengzhou, China.
Hongming PanSir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine, Hangzhou, China.
Jianzhen ShanThe First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Liwei WangRenji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Sang-We KimAsan Medical Center, Seoul, South Korea.
Gary RichardsonCabrini Hospital - Malvern, Malvern, VIC, Australia.
Rachel E SanbornEarle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.ORCID http://orcid.org/0000-0003-0542-6054
Jingdong ZhangLiaoning Cancer Hospital and Institute, Shenyang, China.
Ziyong XiangInventisBio Co., Ltd., Shanghai, China.
Wenjia WangInventisBio Co., Ltd., Shanghai, China.
Zhe ShiInventisBio Co., Ltd., Shanghai, China.
Ling ZhangInventisBio Co., Ltd., Shanghai, China.
Yaolin WangInventisBio Co., Ltd., Shanghai, China.
Rui-Hua XuDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China. xurh@sysucc.org.cn.ORCID http://orcid.org/0000-0001-9771-8534

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGarsorasib (D-1553), a highly selective, oral KRAS

methodsPancreatic cancer patients with KRAS G12C mutation were enroled and received garsorasib 600 mg twice daily treatment in two international, multicenter, open-label phase 1/2 trials (NCT04585035 and NCT05383898) with similar eligibility criteria. Their data were pooled for analyses of efficacy and safety endpoints.

resultsAs of April 30, 2024, 24 KRAS G12C-mutated pancreatic cancer patients were enroled with a median follow-up of 8.9 months (range 1.1-22.9). Among 22 evaluable patients, the confirmed objective response rate (ORR) was 45.5% (95% CI, 24.4 to 67.8) with a median duration of response (DOR) of 6.4 months (95% CI, 4.2 to 16.4). The median progression-free survival (PFS) was 7.6 months (95% CI, 3.3 to 8.5) and the 6-month OS rate was 79.2% (95% CI, 57.0, 90.8). Treatment-related adverse events (TRAEs) occurred in 18 (75.0%) patients, including 6 (25.0%) with grade ≥3 events. No TRAEs led to treatment discontinuation. The safety profile was consistent with previous reports of garsorasib.

conclusionGarsorasib demonstrated encouraging antitumor activity and a tolerable safety profile in patients with KRAS G12C-mutated advanced pancreatic cancer.

Indexed as

Pancreatic NeoplasmsProto-Oncogene Proteins p21(ras)PyrimidinesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationPiperazinesProgression-Free SurvivalPyridinesKRAS protein, humanPiperazinesProto-Oncogene Proteins p21(ras)PyridinesPyrimidinessotorasib

Identifiers

PMID41345264
PMCPMC12852711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.